Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Capital Expenditures (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Capital Expenditures for 16 consecutive years, with $27000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Capital Expenditures rose 92.86% to $27000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $48000.0, a 72.88% decrease, with the full-year FY2024 number at $146000.0, down 8.75% from a year prior.
  • Capital Expenditures was $27000.0 for Q3 2025 at Plus Therapeutics, up from $7000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $210000.0 in Q1 2022 to a low of $3000.0 in Q1 2025.
  • A 5-year average of $58500.0 and a median of $36500.0 in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: surged 663.64% in 2021, then crashed 92.5% in 2025.
  • Plus Therapeutics' Capital Expenditures stood at $84000.0 in 2021, then skyrocketed by 52.38% to $128000.0 in 2022, then plummeted by 67.19% to $42000.0 in 2023, then tumbled by 73.81% to $11000.0 in 2024, then soared by 145.45% to $27000.0 in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Capital Expenditures are $27000.0 (Q3 2025), $7000.0 (Q2 2025), and $3000.0 (Q1 2025).